



Press Release

Thursday, October 18, 2012



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB RECEIVES 2 MORE APPROVALS FOR ONCOLOGY PRODUCTS FROM USFDA

Approval for Fludarabine & Idarubicin Injections

October 18, 2012: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received two more ANDA approvals for

- Fludarabine Phosphate for Injection, USP packaged in 50 mg/ 2 mL, Single use vials (25 mg/mL upon reconstitution) – Lyophilized format and
- Idarubicin Hydrochloride Injection, 1 mg/ mL -5 mL, 10 mL and 20 mL Single-dose vials.


The combined market for the two drugs is approximately USD 20 Million.

Fludarabine is a chemotherapy drug used to treat chronic lymphocytic leukemia (a type of cancer of the white blood cells) in adults.

Idarubicin belongs to the group of cancer-fighting medications known as *antineoplastics*. Idarubicin is used alone or in combination with other antineoplastic medications to treat leukemia.

About Agila Specialties

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencyclins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick
Mr. Ajay Singh : +91 80 6784 0813	Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Kannan N : +91 98450 54745 (Investors)	Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in

